Financial Consulate’s Co-Diagnostics CODX Stock Holding History

Financial Consulate’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500	Closed	-$290K	–	102
2020 Q2	$290K	Hold	500	–	–	0.15%	77
2020 Q1	$114K	Buy	+500	New	+$86.7K	0.07%	93

Other funds holding CODX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

IFG Advisory Atlanta, Georgia $34.9M AUM 20.48% 1-Year Est. Return

Financial Consulate's CODX Position: Q3 2020 in Review

Financial Consulate sold out of Co-Diagnostics (CODX) in Q3 2020, closing a stake of 500 shares — an estimated $290K sold.

Financial Consulate first reported a position in CODX in Q1 2020 and held it in 2 quarters. The position peaked at $290K in Q2 2020. 81 funds tracked by Wall St. Rank hold CODX as of Q3 2020.

Financial Consulate reported no remaining Co-Diagnostics position as of Q3 2020 after selling out during the quarter.
Financial Consulate sold 500 Co-Diagnostics shares in Q3 2020, an estimated $290K.
Financial Consulate first reported a position in Co-Diagnostics in Q1 2020 and held it in 2 quarters.
Financial Consulate's Co-Diagnostics position peaked at $290K in Q2 2020.
81 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2020.

Based on Financial Consulate's 13F filing for Q3 2020, filed 20 Oct 2020.